Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that company management will present at the following investor conferences:
-
2022 RBC Capital Markets Global Healthcare Conference
- Wednesday, May 18, 2022 at 8:00 am ET
-
UBS Global Healthcare Conference
- Wednesday, May 25, 2022 at 8:30 AM ET
About Pipeline Therapeutics
Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address CNS and neuro-otology conditions. Its flagship program, PIPE-307, has completed a Phase 1 clinical trial in healthy volunteers and has received IND clearance from the FDA to initiate a Phase 1b/2a trial in relapsing-remitting MS patients. For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220511006045/en/
Contacts
Company Contact:
Peter Slover
CFO
ir@pipeline-tx.com
Investor Contact:
Amy Conrad
858-914-1962
amy@juniper-point.com
